Amgen's process patent describes the production of its erythropoietin product, Epogen, by expression of the cloned human EPO cDNA sequence, by placing the simian viral DNA promoter (SV40 ...

It has its own patent-protected DNA-encoded library drug discovery technology, which enables the efficient discovery of small molecule drug candidates, according to Amgen. The companies have been ...

Amgen (Thousand Oaks ... limitations that the host cell be “transformed or transfected” or that the EPO DNA be “exogenous.“ These limitations are not found in the US counterpart and ...